Catalyst Wire Dossier Catalyst Wire Dossier

Autologous erythrocyte-derived MPs carrying methotrexate for peritoneal perfusion

methotrexate peritoneal perfusion via autologous erythrocyte-derived MPs
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Autologous erythrocyte-derived MPs carrying methotrexate for peritoneal perfusion, covering 2017-07-26 to 2017-07-26. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites [Phase 1, Phase 2]

See pricing